Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GLB1 | P16278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102196 | 0.95 | GBA1 (0.39) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL23872561 | 0.95 | GBA1 (0.39) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL24842356 | 0.88 | GBA1 (0.38) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL5545683 | 0.87 | HTR7 (0.45) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL24818999 | 0.85 | HTR7 (0.44) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL21351069 | 0.85 | HTR7 (0.44) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL24773751 | 0.84 | GBA1 (0.45) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL21210655 | 0.82 | GUSB (0.55) | GBA1SIGMAR1GLB1 | |
| SCHEMBL6674827 | 0.82 | GUSB (0.55) | GBA1SIGMAR1GLB1 | |
| SCHEMBL6674218 | 0.82 | GUSB (0.55) | GBA1SIGMAR1GLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | ENTPD5, NT5E, ENTPD1 | GBA1 1338/4885DRD2 3607/4885DRD1 4353/4885 |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | ENTPD5, ENTPD1, NT5E | GBA1 1457/4885DRD2 3646/4885DRD1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.